Trump’s new drug pricing executive order may disrupt pricing of Indian Pharma Companies
DSIJ Intelligence / 16 Jun 2017
The top pharma companies in the country draw nearly 40% of the revenue from the US market. As per market observers, the pharma market in the country is getting crowded and the top companies have been witnessing strong threat from new entrants.
The Trump administration is planning to bring in drug pricing executive orderin order to lower the drugs and medicines prices in the US. Trump administration is seeking for recommendations from the nation’s health agencies on reducing medication costs.
A leading news agency reported that drug pricing executive order may come out soon, which may disrupt the profitability of Indian pharmaceutical companies. The top pharma companies in the country draw nearly 40% of the revenue from the US market. As per market observers, the pharma market in the country is getting crowded and the top companies have been witnessing strong threat from new entrants.
Investors in India are worried due to price erosion in the US market and pharma stocks have been losing on the bourses. In Friday’s trading session, Lupin, and Ipca Labs are top losers in pharma space, trading lower by up to 9%. Other major pharma stocks like Sun Pharma, Cipla, Dr Reddy’s, Cadila and Divi’s Lab are also trading in red zone.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.